KAKAKU.COM
26.6.2024 15:01:31 CEST | Business Wire | Press release
Tabelog*2, one of Japan’s largest restaurant search and reservation sites, has launched an online reservation service for visitors to Japan, which supports English, Chinese (Simplified and Traditional) and Korean. With reservations available at over 35,000 restaurants, it is the largest service of its kind in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626189960/en/
Reservation Flow (Graphic: Business Wire)
*1As of June 26, 2024, based on internal research. Largest restaurant reservation service (instant reservations) for visitors to Japan
*2Tabelog is operated by Kakaku.com, Inc. one of Japan’s leading Internet companies.
Tabelog’s online reservation service for overseas visitors
To offer a more convenient way to find and reserve restaurants for the growing number of visitors to Japan, we have launched an online restaurant reservation service where reservations can be made in English, Chinese (Traditional and Simplified), and Korean.
*According to the Japan National Tourism Organization, the number of visitors to Japan is expected to exceed 3 million in May 2024 (up 60% from the previous year).
Features of Tabelog’s service are as follows:
- Search for restaurants in Japan by specifying a location, cuisine, budget, and the date and time you want to make a reservation.
- Select a restaurant based on detailed information about the restaurant, including menu, photos, and reviews posted by Japanese users.
-
Check reservation availability using the calendar function and make online reservations directly on Tabelog.
*Online reservations are currently only available for set menus and require credit card registration. In addition, there is a system usage fee of 440 yen (incl. tax) per person per reservation.
“Japan is currently the destination of choice for travelers from around the world, and many of them want to experience Japan’s food culture. However, there is still a shortage of restaurants equipped to communicate with and take reservations from overseas visitors leading to a situation where only a handful of well-known restaurants are attracting visitors to Japan,” said Taku Kounoike, Head of Tabelog. “As a Japanese gourmet media, we want to support travelers in experiencing the deeper charm of Japan, by showcasing a wide range of excellent restaurants across the country, and by providing a service that enables users to make online reservations. We sincerely hope that your travel experience in Japan will become more fulfilling than ever before.”
Links to the different language versions of Tabelog:
- English: https://tabelog.com/en/
- Simplified Chinese: https://tabelog.com/cn/
- Traditional Chinese: https://tabelog.com/tw/
- Korean: https://tabelog.com/kr/
*Ongoing modifications and improvements to the site may result in changes to the user interface and performance.
About Tabelog
Tabelog provides information on almost all restaurants in Japan, and users can choose restaurants catering to their specific preferences, based on information provided by the restaurants themselves, as well as reviews and photos posted by users. The service receives high marks from users for offering comprehensive information about restaurants and a highly convenient user interface. As of March 2024, it has become one of Japan’s largest restaurant search and reservation services, with approximately 93.5 million monthly users.
About Kakaku.com, Inc. (https://corporate.kakaku.com/?lang=en)
Established in 1997, Kakaku.com, Inc. (TOKYO:2371) is a Japanese internet company operating various web services, including the purchasing support site "Kakaku.com", the restaurant search and reservation service "Tabelog", and the comprehensive job search service "Kyujin Box". In April 2024, the company launched "Jobcube", a comprehensive search site for jobseekers, in the United States.
Service Overview: https://corporate.kakaku.com/company/service/?lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626189960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom